Bottom-Up EquitiesDaily Briefs

Equity Bottom-Up: SUMCO Corp, Green Cross and more

In today’s briefing:

  • SUMCO (3436 JP): CEO Describes Tight Supply, Rising Prices
  • Green Cross (006280 KS): Look Ahead for Key Milestones Amid Covid Vaccine Related Setback

SUMCO (3436 JP): CEO Describes Tight Supply, Rising Prices

By Scott Foster

  • CEO Hashimoto told the Nikkei newspaper that customers are ordering silicon wafers at higher prices before they are made, even as production capacity is being increased.
  • SEMI and TSMC announcements point to rising wafer demand for at least another two years. SUMCO’s expansion plans suggest at least three years.
  • We continue to recommend buying into the current weakness for the medium to long term.

Green Cross (006280 KS): Look Ahead for Key Milestones Amid Covid Vaccine Related Setback

By Tina Banerjee

  • Green Cross (006280 KS) is currently waiting for marketing approval from the FDA for its immune globulin intravenous injection, which will mark its entry into the U.S. market.
  • The company will start commercializing its hemophilia A treatment, GreenGene F in China market this year. As a third-generation product, GreenGene is expected to gain substantial market share.
  • Green Cross shares remained subdued last year, as the company could not finalize a contract manufacturing deal for COVID-19 vaccine.

Related tickers: SUMCO Corp (3436.T), Green Cross (006280.KS)

Before it’s here, it’s on Smartkarma